Agilent Technologies, Inc. (BIT:1A)
Italy
· Delayed Price · Currency is EUR 107.42
+0.12 (0.11%)
At close: Sep 24, 2025
Revenue by Product
Fiscal year is November - October.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | 2012 - 2019 |
| Life Sciences & Diagnostics Markets | 2.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Agilent CrossLab Revenue (Post-FY2024 Reporting) | 2.75B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Applied Markets | 1.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences & Applied Markets | 3.22B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences & Applied Markets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics & Genomics | 1.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics & Genomics Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Agilent CrossLab Revenue (Pre-FY2025 Reporting) | 1.64B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Agilent CrossLab Revenue (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is November - October.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | 2012 - 2019 |
| Other | -177.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences & Diagnostics Markets Income from Operations | 484.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Agilent CrossLab Income from Operations (Post-FY2024 Reporting) | 925.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Applied Markets Income from Operations | 312.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -177.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences & Applied Markets Income from Operations | 877.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences & Applied Markets Income from Operations Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics & Genomics Income from Operations | 320.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics & Genomics Income from Operations Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Agilent CrossLab Income from Operations (Pre-FY2025 Reporting) | 524.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Agilent CrossLab Income from Operations (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|